NCT02718430View on ClinicalTrials.gov

VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Colorectal Cancer
Interventions
DRUG

VXM01

Oral immunotherapy targeting VEGFR2

Trial Locations (1)

69120

National Center of Tumor Diseases, Heidelberg

All Listed Sponsors
lead

Vaximm GmbH

INDUSTRY

NCT02718430 - VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis | Biotech Hunter | Biotech Hunter